دورية أكاديمية
أعرض في EDS

Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present.

التفاصيل البيبلوغرافية
العنوان: Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present.
المؤلفون: Huff SE; Department of Pediatrics, University of California, San Diego, CA 92093, USA., Winter JM; Department of Surgery, Division of Surgical Oncology, University Hospitals Cleveland Medical Center, Akron, OH 44106, USA., Dealwis CG; Department of Pharmacology, Case Western Reserve University, Cleveland, OH 44106, USA.; Department of Chemistry, Case Western Reserve University, Cleveland, OH 44106, USA.
المصدر: Biomolecules [Biomolecules] 2022 Jun 10; Vol. 12 (6). Date of Electronic Publication: 2022 Jun 10.
نوع المنشور: Journal Article; Review; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101596414 Publication Model: Electronic Cited Medium: Internet ISSN: 2218-273X (Electronic) Linking ISSN: 2218273X NLM ISO Abbreviation: Biomolecules Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, 2011-
مواضيع طبية MeSH: Neoplasms*/drug therapy , Ribonucleotide Reductases*/metabolism, Catalytic Domain ; Diphosphates ; Enzyme Inhibitors/pharmacology ; Enzyme Inhibitors/therapeutic use ; Humans
مستخلص: Ribonucleotide reductase (RR) is an essential multi-subunit enzyme found in all living organisms; it catalyzes the rate-limiting step in dNTP synthesis, namely, the conversion of ribonucleoside diphosphates to deoxyribonucleoside diphosphates. As expression levels of human RR (hRR) are high during cell replication, hRR has long been considered an attractive drug target for a range of proliferative diseases, including cancer. While there are many excellent reviews regarding the structure, function, and clinical importance of hRR, recent years have seen an increase in novel approaches to inhibiting hRR that merit an updated discussion of the existing inhibitors and strategies to target this enzyme. In this review, we discuss the mechanisms and clinical applications of classic nucleoside analog inhibitors of hRRM1 (large catalytic subunit), including gemcitabine and clofarabine, as well as inhibitors of the hRRM2 (free radical housing small subunit), including triapine and hydroxyurea. Additionally, we discuss novel approaches to targeting RR and the discovery of new classes of hRR inhibitors.
References: Postepy Biochem. 2015;61(3):274-83. (PMID: 26677574)
Anticancer Drugs. 1995 Dec;6 Suppl 6:7-13. (PMID: 8718419)
Science. 2020 Apr 24;368(6489):424-427. (PMID: 32217749)
World J Gastroenterol. 2019 Oct 7;25(37):5590-5603. (PMID: 31602160)
Leuk Lymphoma. 2007 Oct;48(10):1922-30. (PMID: 17852710)
J Am Chem Soc. 2005 Jun 1;127(21):7729-38. (PMID: 15913363)
Cancer Res. 1989 Dec 15;49(24 Pt 1):6923-8. (PMID: 2573423)
Invest New Drugs. 1992 Apr;10(1):27-8. (PMID: 1318870)
Lung Cancer. 2012 Mar;75(3):374-80. (PMID: 21889227)
Clin Cancer Res. 2021 Jun 15;27(12):3383-3396. (PMID: 33674273)
Biochemistry. 1994 Mar 15;33(10):2838-42. (PMID: 8130196)
J Clin Oncol. 2004 Jan 1;22(1):157-65. (PMID: 14701778)
J Biol Chem. 2012 Oct 12;287(42):35768-35778. (PMID: 22915594)
J Biol Chem. 2011 Apr 1;286(13):11132-40. (PMID: 21297166)
Int J Pharm. 2018 Mar 1;538(1-2):79-86. (PMID: 29341909)
J Biol Chem. 1992 Jun 25;267(18):12627-31. (PMID: 1618768)
ACS Nano. 2019 Feb 26;13(2):2176-2189. (PMID: 30676731)
Cancer. 1999 Mar 15;85(6):1261-8. (PMID: 10189130)
Exp Hematol. 2003 Jul;31(7):586-91. (PMID: 12842703)
Invest New Drugs. 1999;17(2):173-7. (PMID: 10638488)
Cancer Sci. 2021 Jan;112(1):410-421. (PMID: 32770631)
Cancer Chemother Pharmacol. 2009 May;63(6):1147-56. (PMID: 19082825)
J Med Chem. 2008 Aug 14;51(15):4653-9. (PMID: 18610997)
Oncologist. 1996;1(3):125-139. (PMID: 10387979)
Cancer Chemother Pharmacol. 2010 Mar;65(4):679-86. (PMID: 19639316)
Antiviral Res. 2006 Sep;71(2-3):122-6. (PMID: 16621038)
Clin Ther. 2021 Jun;43(6):1107-1115. (PMID: 34059328)
J Biol Chem. 2006 Apr 21;281(16):10691-7. (PMID: 16481328)
J Mol Biol. 1969 Nov 28;46(1):39-55. (PMID: 4902212)
J Biol Chem. 1990 Apr 5;265(10):5329-32. (PMID: 2180924)
Biochemistry. 1992 Oct 13;31(40):9733-43. (PMID: 1382592)
Semin Oncol. 1992 Jun;19(3 Suppl 9):21-6. (PMID: 1641653)
Cancer Res. 1998 Mar 15;58(6):1165-9. (PMID: 9515801)
J Med Chem. 1988 Jun;31(6):1063-4. (PMID: 3373480)
Clin Cancer Res. 2001 Nov;7(11):3580-9. (PMID: 11705880)
Cancer Res. 2005 Oct 15;65(20):9510-6. (PMID: 16230416)
J Enzyme Inhib Med Chem. 2019 Dec;34(1):438-450. (PMID: 30734609)
Curr Opin Chem Biol. 2003 Apr;7(2):183-8. (PMID: 12714050)
Neoplasma. 1988;35(1):27-35. (PMID: 3162554)
Oncogene. 2021 Jan;40(1):215-231. (PMID: 33110235)
J Biol Inorg Chem. 2019 Sep;24(6):841-848. (PMID: 31218442)
Mol Cancer. 2009 Feb 28;8:11. (PMID: 19250552)
Haematologica. 2014 Apr;99(4):672-8. (PMID: 24362550)
Transl Oncol. 2015 Jun;8(3):210-6. (PMID: 26055179)
Cancer. 2018 Mar 15;124(6):1150-1159. (PMID: 29266189)
Cancer Res. 1995 Mar 15;55(6):1328-33. (PMID: 7882331)
Pharmacol Rev. 1998 Dec;50(4):665-82. (PMID: 9860806)
FEBS Lett. 1990 Oct 15;272(1-2):61-4. (PMID: 2226836)
J Biol Inorg Chem. 2020 Jun;25(4):571-582. (PMID: 32296998)
J Thorac Oncol. 2008 Oct;3(10):1112-8. (PMID: 18827606)
Adv Enzyme Regul. 1991;31:71-83. (PMID: 1877400)
Mol Pharmacol. 2002 Jan;61(1):222-9. (PMID: 11752224)
Cancer Res. 1990 Jun 15;50(12):3675-80. (PMID: 2340517)
Chem Biol. 1995 Dec;2(12):793-801. (PMID: 8807812)
Histopathology. 2010 Dec;57(6):885-92. (PMID: 21166702)
Cancer Biol Ther. 2002 Sep-Oct;1(5):539-45. (PMID: 12496485)
Clin Genitourin Cancer. 2008 Sep;6(2):73-8. (PMID: 18824428)
Cancer Chemother Pharmacol. 1994;34(1):63-6. (PMID: 8174204)
Blood. 2000 Nov 15;96(10):3537-43. (PMID: 11071652)
Cancer Res. 1979 Mar;39(3):844-51. (PMID: 427774)
Cancer Res. 1992 Feb 1;52(3):533-9. (PMID: 1732039)
Proc Natl Acad Sci U S A. 1981 Apr;78(4):2447-51. (PMID: 7017732)
Control Clin Trials. 1995 Dec;16(6):432-46. (PMID: 8925656)
Proc Natl Acad Sci U S A. 2007 Sep 4;104(36):14324-9. (PMID: 17726094)
Cancer Res. 1990 Aug 15;50(16):4929-30. (PMID: 2379156)
J Neurooncol. 2010 Feb;96(3):393-402. (PMID: 19688297)
Cancer Res. 1995 Apr 1;55(7):1517-24. (PMID: 7533664)
J Pharmacol Exp Ther. 2007 Sep;322(3):1228-36. (PMID: 17600139)
Int J Gynecol Cancer. 2005 May-Jun;15 Suppl 1:36-41. (PMID: 15839957)
Biochem Pharmacol. 2002 Aug 1;64(3):481-5. (PMID: 12147300)
Clin Cancer Res. 2008 Mar 1;14(5):1284-5. (PMID: 18316544)
Cancer J. 2000 Sep-Oct;6(5):309-15. (PMID: 11079170)
J Clin Oncol. 2007 May 20;25(15):1960-6. (PMID: 17452677)
Cancer Res. 1991 Nov 15;51(22):6199-201. (PMID: 1933878)
Cancer Res. 2001 Feb 1;61(3):1073-9. (PMID: 11221835)
J Neurooncol. 2007 May;83(1):53-60. (PMID: 17245623)
Br J Cancer. 1990 Mar;61(3):447-50. (PMID: 2183873)
Semin Oncol. 1992 Jun;19(3 Suppl 9):11-9. (PMID: 1641651)
Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):961-7. (PMID: 25832688)
Elife. 2016 Jan 12;5:e07141. (PMID: 26754917)
J Gastroenterol. 2007 May;42(5):389-94. (PMID: 17530364)
Jpn J Clin Oncol. 2019 Feb 1;49(2):190-194. (PMID: 30608598)
Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1531-5. (PMID: 15571292)
J Med Chem. 2018 Feb 8;61(3):666-680. (PMID: 29253340)
Biochim Biophys Acta. 2009 Jul;1790(7):702-17. (PMID: 18485918)
Pharmacol Rev. 2005 Dec;57(4):547-83. (PMID: 16382108)
J Biol Chem. 1992 Feb 5;267(4):2345-9. (PMID: 1310314)
Anticancer Res. 2011 Nov;31(11):3747-56. (PMID: 22110196)
Science. 1996 Jan 26;271(5248):477-81. (PMID: 8560260)
N Engl J Med. 2011 May 12;364(19):1817-25. (PMID: 21561347)
Nat Rev Drug Discov. 2005 May;4(5):369-70. (PMID: 15902772)
Clin Cancer Res. 2009 Oct 15;15(20):6462-71. (PMID: 19825958)
FEBS Lett. 1995 Oct 23;374(1):95-9. (PMID: 7589521)
Mol Oncol. 2016 Nov;10(9):1375-1386. (PMID: 27511871)
Cancer Res. 2004 Jun 1;64(11):3761-6. (PMID: 15172981)
Nature. 2000 Mar 2;404(6773):42-9. (PMID: 10716435)
Ann Oncol. 2009 Mar;20(3):449-53. (PMID: 19087987)
Anticancer Drugs. 2007 Apr;18(4):377-88. (PMID: 17351390)
Anticancer Res. 1995 Jul-Aug;15(4):1179-82. (PMID: 7653997)
J Clin Oncol. 2009 Dec 1;27(34):5808-15. (PMID: 19884554)
J Thorac Oncol. 2011 Apr;6(4):786-9. (PMID: 21289521)
J Med Chem. 2015 Dec 24;58(24):9498-509. (PMID: 26488902)
J Med Chem. 1991 Feb;34(2):812-9. (PMID: 1995905)
Philos Trans R Soc Lond B Biol Sci. 2006 Aug 29;361(1472):1351-64. (PMID: 16873123)
Cancer Res. 2003 Jun 1;63(11):2802-11. (PMID: 12782585)
Eur J Nucl Med. 1988;14(3):155-8. (PMID: 3042424)
Cancer Treat Rep. 1987 Nov;71(11):1099-100. (PMID: 2824047)
Cytometry. 1999 Dec 1;37(4):302-7. (PMID: 10547615)
Neuro Oncol. 2008 Oct;10(5):752-8. (PMID: 18715950)
Prog Med Chem. 1978;15:321-56. (PMID: 400614)
Pharmaceuticals (Basel). 2011 Oct 13;4(10):1328-1354. (PMID: 23115527)
JAMA. 2016 May 3;315(17):1844-53. (PMID: 27139057)
Drugs. 2000;60 Suppl 1:15-23; discussion 41-2. (PMID: 11129168)
Br J Cancer. 1991 Dec;64(6):1187-8. (PMID: 1764386)
J Cancer Res Clin Oncol. 2017 Aug;143(8):1499-1529. (PMID: 28624910)
J Biol Chem. 1996 Aug 23;271(34):20291-9. (PMID: 8702762)
Adv Enzyme Regul. 1980;19:151-68. (PMID: 6175187)
Ann Hematol. 2019 Mar;98(3):561-579. (PMID: 30470874)
Biochem Pharmacol. 1986 Aug 15;35(16):2781-7. (PMID: 3527174)
Cancer Res. 1994 Apr 1;54(7 Suppl):1890s-1894s. (PMID: 8137306)
Cancer Chemother Pharmacol. 1998;41(4):268-74. (PMID: 9488595)
World J Gastroenterol. 2012 Sep 14;18(34):4704-13. (PMID: 23002339)
Oncotarget. 2017 May 16;8(43):73905-73924. (PMID: 29088756)
Leuk Lymphoma. 2001 Feb;40(5-6):671-4. (PMID: 11426540)
N Engl J Med. 2005 Jul 7;353(1):33-45. (PMID: 16000354)
Elife. 2018 Feb 20;7:. (PMID: 29460780)
Semin Oncol. 1992 Jun;19(3 Suppl 9):1-10. (PMID: 1641648)
Curr Cancer Drug Targets. 2006 Aug;6(5):409-31. (PMID: 16918309)
Gan To Kagaku Ryoho. 1996 Nov;23(13):1799-811. (PMID: 8937491)
Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4022-7. (PMID: 16537479)
Eur J Cancer. 2011 Apr;47(6):839-47. (PMID: 21220199)
Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1069-76. (PMID: 18977094)
Curr Opin Investig Drugs. 2001 Oct;2(10):1462-6. (PMID: 11890366)
Ann Oncol. 2006 Dec;17(12):1818-25. (PMID: 16980606)
Proc Natl Acad Sci U S A. 2012 Jun 19;109(25):9798-803. (PMID: 22665797)
Leuk Res. 2007 Sep;31(9):1165-73. (PMID: 17324462)
Int J Biochem Cell Biol. 2015 Mar;60:73-81. (PMID: 25562513)
Anticancer Res. 2006 Mar-Apr;26(2A):983-8. (PMID: 16619496)
Clin Cancer Res. 1998 Feb;4(2):493-7. (PMID: 9516941)
Trends Biochem Sci. 1998 Nov;23(11):438-43. (PMID: 9852763)
Am J Hematol. 2000 Nov;65(3):227-33. (PMID: 11074540)
J Clin Oncol. 2004 May 1;22(9):1553-63. (PMID: 15117978)
Curr Opin Investig Drugs. 2000 Sep;1(1):135-40. (PMID: 11249589)
Free Radic Biol Med. 2014 Jan;66:75-87. (PMID: 23899494)
Cytogenet Cell Genet. 2001;95(1-2):34-42. (PMID: 11978967)
Am J Hematol. 2000 Apr;63(4):176-83. (PMID: 10706760)
Proc Natl Acad Sci U S A. 2003 May 13;100(10):5974-9. (PMID: 12714683)
Chem Rev. 2003 Jun;103(6):2167-201. (PMID: 12797828)
Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):831-8. (PMID: 17560737)
Cancer Res. 2016 Feb 15;76(4):902-11. (PMID: 26837770)
Clin Pharmacokinet. 2000 Jun;38(6):475-91. (PMID: 10885585)
Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4028-33. (PMID: 16537480)
BMC Cancer. 2016 May 12;16:305. (PMID: 27175473)
Cancer Res. 2008 Apr 15;68(8):2652-60. (PMID: 18413732)
Structure. 1997 Aug 15;5(8):1077-92. (PMID: 9309223)
J Clin Oncol. 2006 Oct 10;24(29):4731-7. (PMID: 16966686)
Leuk Res. 2003 Dec;27(12):1077-83. (PMID: 12921943)
Free Radic Biol Med. 1995 Nov;19(5):533-9. (PMID: 8529912)
Biochem Pharmacol. 1989 Nov 15;38(22):4115-21. (PMID: 2688654)
Dalton Trans. 2012 Jun 7;41(21):6371-89. (PMID: 22391807)
Bioorg Med Chem Lett. 2000 Oct 16;10(20):2387-9. (PMID: 11055362)
Mol Cancer. 2022 May 10;21(1):112. (PMID: 35538494)
J Biol Chem. 2006 Sep 22;281(38):27705-11. (PMID: 16861739)
Leuk Res. 2008 Jan;32(1):71-7. (PMID: 17640728)
Chemistry. 2003 Dec 5;9(23):5916-25. (PMID: 14673863)
Oncogene. 2009 Aug 13;28(32):2903-9. (PMID: 19543324)
Hum Pathol. 2010 Dec;41(12):1742-8. (PMID: 20825972)
Chem Biol. 2012 Jul 27;19(7):799-805. (PMID: 22840768)
Nature. 1986 May 22-28;321(6068):439-41. (PMID: 3012359)
Invest New Drugs. 1996;14(4):409-13. (PMID: 9157078)
Nature. 2010 Apr 15;464(7291):1067-70. (PMID: 20305636)
Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):10022-10027. (PMID: 30224458)
Adv Enzyme Regul. 1995;35:55-68. (PMID: 7572354)
J Neurooncol. 2008 Feb;86(3):353-8. (PMID: 18175205)
Curr Med Chem. 2001 Feb;8(2):121-33. (PMID: 11172670)
Cancer. 2011 Jan 15;117(2):318-26. (PMID: 20830768)
Blood. 1994 Dec 15;84(12):4316-21. (PMID: 7994048)
Biochemistry. 2003 Feb 18;42(6):1696-706. (PMID: 12578384)
Anticancer Res. 1994 Sep-Oct;14(5B):2109-12. (PMID: 7840508)
Br J Cancer. 1988 Jul;58(1):70-2. (PMID: 3048353)
Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9815-20. (PMID: 21628579)
Biochem Cell Biol. 1991 Jan;69(1):79-83. (PMID: 2043345)
Antioxid Redox Signal. 2013 Mar 10;18(8):973-1006. (PMID: 22424293)
Cancer Res. 1991 May 1;51(9):2386-94. (PMID: 1707752)
J Neurooncol. 2004 May;67(3):367-77. (PMID: 15164994)
Bioorg Med Chem Lett. 2014 Nov 15;24(22):5304-9. (PMID: 25304896)
Leuk Lymphoma. 2009 Dec;50(12):1977-82. (PMID: 19860624)
Genes (Basel). 2017 Jan 31;8(2):. (PMID: 28146119)
Biochemistry. 2010 Feb 23;49(7):1396-403. (PMID: 20088568)
Oncol Rep. 2008 Aug;20(2):279-86. (PMID: 18636187)
J Clin Oncol. 2008 Jul 20;26(21):3543-51. (PMID: 18506025)
ACS Chem Biol. 2016 Jul 15;11(7):2021-32. (PMID: 27159113)
J Clin Oncol. 2020 May 10;38(14):1527-1538. (PMID: 32109194)
Mol Cancer Ther. 2005 Aug;4(8):1268-76. (PMID: 16093443)
Invest New Drugs. 2008 Apr;26(2):169-73. (PMID: 17851637)
Clin Cancer Res. 2002 Aug;8(8):2499-504. (PMID: 12171875)
Curr Opin Investig Drugs. 2001 Oct;2(10):1467-70. (PMID: 11890367)
J Med Chem. 1991 Jun;34(6):1879-84. (PMID: 2061926)
Crit Rev Biochem Mol Biol. 2012 Jan-Feb;47(1):50-63. (PMID: 22050358)
Cell Death Dis. 2015 Oct 15;6:e1913. (PMID: 26469962)
Cell Cycle. 2014;13(2):199-207. (PMID: 24200970)
Ann Oncol. 2009 Jul;20(7):1275-9. (PMID: 19246715)
Oncogene. 2019 Mar;38(13):2364-2379. (PMID: 30518875)
Res Commun Chem Pathol Pharmacol. 1990 Feb;67(2):219-27. (PMID: 2333410)
Clin Sci (Lond). 2013 May;124(9):567-78. (PMID: 23113760)
Expert Opin Ther Targets. 2011 Jul;15(7):817-28. (PMID: 21391891)
J Neurooncol. 2011 Nov;105(2):301-8. (PMID: 21523486)
Mol Pharmacol. 1994 Apr;45(4):792-6. (PMID: 8183256)
Annu Rev Biochem. 2020 Jun 20;89:45-75. (PMID: 32569524)
Cancer Lett. 2006 Feb 20;233(1):178-84. (PMID: 15885888)
Mol Pharmacol. 2015 Jun;87(6):996-1005. (PMID: 25814515)
Drug Resist Updat. 2015 Nov;23:55-68. (PMID: 26690340)
Sci Rep. 2016 Feb 01;6:19973. (PMID: 26829331)
Eur J Clin Chem Clin Biochem. 1995 Nov;33(11):785-9. (PMID: 8620054)
Cancer. 2005 May 15;103(10):1985-95. (PMID: 15803490)
Eur J Med Chem. 2005 Jan;40(1):51-5. (PMID: 15642408)
Nat Struct Mol Biol. 2011 Mar;18(3):316-22. (PMID: 21336276)
FEBS Lett. 2000 Feb 4;467(1):27-30. (PMID: 10664450)
Oncol Rep. 2020 Sep;44(3):1158-1168. (PMID: 32705228)
Carcinogenesis. 2012 Nov;33(11):2172-80. (PMID: 22828135)
Int J Cancer. 2007 Mar 15;120(6):1355-63. (PMID: 17131328)
Biochem Biophys Res Commun. 1992 Oct 30;188(2):879-87. (PMID: 1332707)
Nature. 2018 Nov;563(7731):416-420. (PMID: 30429545)
J Biol Chem. 1980 Nov 10;255(21):10502-8. (PMID: 6253477)
Eur J Clin Pharmacol. 2000 Nov;56(8):567-74. (PMID: 11151746)
Cancer. 2005 May 1;103(9):1925-31. (PMID: 15772958)
J Clin Oncol. 1997 Jun;15(6):2403-13. (PMID: 9196156)
Biochemistry. 2016 Jan 19;55(2):373-81. (PMID: 26727048)
Invest New Drugs. 2007 Oct;25(5):471-7. (PMID: 17393073)
J Biol Chem. 1990 Sep 25;265(27):16617-25. (PMID: 1697861)
Cancer Chemother Pharmacol. 2003 Jul;52(1):41-6. (PMID: 12690517)
Cancer. 2003 Apr 15;97(8):1985-90. (PMID: 12673728)
Drugs. 1994;47 Suppl 6:39-49. (PMID: 7525188)
N Engl J Med. 2010 Apr 29;362(17):1605-17. (PMID: 20427809)
Crit Rev Oncog. 2019;24(2):199-212. (PMID: 31679214)
Semin Oncol. 1996 Oct;23(5 Suppl 10):3-15. (PMID: 8893876)
Biochem Pharmacol. 2006 Aug 28;72(5):573-81. (PMID: 16822479)
Bioorg Med Chem. 2009 Mar 15;17(6):2360-5. (PMID: 19251420)
N Engl J Med. 2018 Dec 20;379(25):2395-2406. (PMID: 30575490)
World J Gastroenterol. 2014 Aug 21;20(31):10825-44. (PMID: 25152585)
Acc Chem Res. 2013 Nov 19;46(11):2524-35. (PMID: 23730940)
Biochemistry. 1991 May 28;30(21):5164-71. (PMID: 2036382)
Nature. 1986 May 22-28;321(6068):441-3. (PMID: 3012360)
Cancer Res. 2013 Nov 1;73(21):6484-93. (PMID: 24072748)
Cancer Chemother Pharmacol. 2004 Aug;54(2):139-45. (PMID: 15133626)
Chin Med J (Engl). 2012 Jun;125(12):2151-6. (PMID: 22884145)
J Biol Chem. 1970 Oct 25;245(20):5228-33. (PMID: 4319235)
Semin Oncol. 1991 Aug;18(4 Suppl 5):3. (PMID: 1925628)
Biochem Pharmacol. 1994 Jul 19;48(2):335-44. (PMID: 8053929)
Semin Hematol. 1994 Jan;31(1):28-39. (PMID: 7510070)
Carcinogenesis. 2021 Apr 30;42(4):546-556. (PMID: 33624791)
J Thorac Oncol. 2007 Aug;2(8):745-50. (PMID: 17762342)
JACS Au. 2021 Jun 28;1(6):865-878. (PMID: 34240081)
Invest New Drugs. 1998-1999;16(3):245-54. (PMID: 10360604)
Leuk Lymphoma. 1994;14 Suppl 2:3-9. (PMID: 7881348)
Blood Rev. 1994 Sep;8(3):125-34. (PMID: 7819814)
Clin Cancer Res. 2002 Sep;8(9):2828-34. (PMID: 12231523)
Oncotarget. 2016 Aug 9;7(32):51301-51310. (PMID: 27322077)
Presse Med. 2019 Mar;48(3 Pt 2):e159-e174. (PMID: 30879894)
Eur J Biochem. 2000 Oct;267(20):6102-9. (PMID: 11012661)
Mol Cancer Ther. 2006 Mar;5(3):586-92. (PMID: 16546972)
Lancet Oncol. 2011 Jul;12(7):693-702. (PMID: 21163702)
PLoS One. 2014 Mar 19;9(3):e92320. (PMID: 24647522)
Cancer Sci. 2008 Oct;99(10):2083-96. (PMID: 19016770)
Free Radic Biol Med. 2004 Sep 15;37(6):737-44. (PMID: 15304249)
Hum Exp Toxicol. 2002 Feb;21(2):71-5. (PMID: 12102499)
Oncogene. 2015 Apr 16;34(16):2011-21. (PMID: 24909171)
Cancer Chemother Pharmacol. 2004 Oct;54(4):331-42. (PMID: 15148626)
Invest New Drugs. 1987 Dec;5(4):365-71. (PMID: 3436742)
Recent Pat Anticancer Drug Discov. 2007 Jan;2(1):11-29. (PMID: 18221051)
Biochem Pharmacol. 1995 Mar 30;49(7):947-54. (PMID: 7741767)
N Engl J Med. 2013 Oct 31;369(18):1691-703. (PMID: 24131140)
Anticancer Drugs. 1998 Aug;9(7):653-7. (PMID: 9773810)
Nat Struct Mol Biol. 2004 Nov;11(11):1142-9. (PMID: 15475969)
J Gastroenterol Hepatol. 2021 Apr;36(4):1103-1109. (PMID: 33002234)
Mol Cancer Ther. 2012 Oct;11(10):2077-86. (PMID: 22933704)
Eur J Biochem. 1969 Jul;9(4):561-73. (PMID: 4896737)
Cancer Treat Rep. 1987 Apr;71(4):349-52. (PMID: 3548956)
Cell Rep. 2013 Apr 25;3(4):1252-65. (PMID: 23562156)
Int J Cancer. 2005 Sep 10;116(4):640-5. (PMID: 15818619)
Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):8241-8246. (PMID: 28716944)
J Mol Biol. 2012 Jun 22;419(5):315-29. (PMID: 22465672)
Oncogene. 2004 Feb 26;23(8):1539-48. (PMID: 14661056)
معلومات مُعتمدة: 1R01GM100887-01 United States TR NCATS NIH HHS; UL1TR002548 Clinical and Translational Science Collaborative of Cleveland; R01 CA212600 United States CA NCI NIH HHS; R37 CA227865 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: COH 29; acyl hydrazone; breast cancer; cancer chemotherapy; cladribine; clofarabine; drug discovery; fludarabine; gemcitabine; hydrazone; pancreatic cancer; ribonucleotide reductase; ribonucleotide reductase inhibitors; small cell lung cancer; small molecule; triapine
المشرفين على المادة: 0 (Diphosphates)
0 (Enzyme Inhibitors)
EC 1.17.4.- (Ribonucleotide Reductases)
تواريخ الأحداث: Date Created: 20220624 Date Completed: 20220627 Latest Revision: 20220716
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9221315
DOI: 10.3390/biom12060815
PMID: 35740940
قاعدة البيانات: MEDLINE
الوصف
تدمد:2218-273X
DOI:10.3390/biom12060815